Cartesian Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Cartesian Therapeutics, Inc. (RNAC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.08M, a 36.47% decline year-over-year.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.42M, a 3.39% decline year-over-year.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.59M, a 52.80% increase year-over-year.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.28M, a 106.10% increase year-over-year.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.52M, a 59.85% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.58M, a 68.60% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $20.96M, a 105.65% increase from fiscal 2022.
- Cartesian Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.19M, a 32.05% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-06 | $4.51M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.42M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $10.52M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-06 | $8.38M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.28M 10-Q · filed 2026-08-06 | $5.79M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.51M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $6.58M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $1.70M 10-Q · filed 2025-11-06 | $3.29M derived: sum of 2 quarters · filed 2025-11-06 | $4.72M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.59M 10-Q · filed 2025-11-06 | $3.02M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $1.43M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $20.96M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $2.32M 10-Q · filed 2024-11-07 | $4.60M derived: sum of 2 quarters · filed 2024-11-07 | $6.88M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.28M 10-Q · filed 2024-11-07 | $4.56M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.28M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $10.19M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $2.60M 10-Q · filed 2023-11-13 | $5.17M derived: sum of 2 quarters · filed 2023-11-13 | $7.92M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $2.56M 10-Q · filed 2023-11-13 | $5.32M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $2.75M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $7.72M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-03 | $3.69M derived: sum of 2 quarters · filed 2022-11-03 | $5.47M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $1.78M 10-Q · filed 2022-11-03 | $3.56M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $1.78M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $5.42M 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $1.30M 10-Q · filed 2021-11-09 | $2.78M derived: sum of 2 quarters · filed 2021-11-09 | $4.19M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $1.48M 10-Q · filed 2021-11-09 | $2.89M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $1.41M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $5.16M 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $1.30M 10-Q · filed 2020-11-05 | $2.55M derived: sum of 2 quarters · filed 2020-11-05 | $3.73M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $1.25M 10-Q · filed 2020-11-05 | $2.43M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $1.18M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $5.71M 10-K · filed 2021-03-12 | |||
| 2018-09-30 | $1.53M 10-Q · filed 2019-11-08 | $2.77M derived: sum of 2 quarters · filed 2019-11-08 | $3.92M derived: sum of 3 quarters · filed 2019-11-08 | $5.13M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $1.25M 10-Q · filed 2019-11-08 | $2.40M derived: sum of 2 quarters · filed 2019-11-08 | $3.61M derived: sum of 3 quarters · filed 2020-03-12 | $4.92M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $1.15M 10-Q · filed 2019-11-08 | $2.36M derived: sum of 2 quarters · filed 2020-03-12 | $3.67M derived: sum of 3 quarters · filed 2020-03-12 | $4.54M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.52M derived: sum of 2 quarters · filed 2020-03-12 | $3.39M derived: sum of 3 quarters · filed 2020-03-12 | $4.08M 10-K · filed 2020-03-12 |
| 2017-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.18M derived: sum of 2 quarters · filed 2017-11-07 | $2.87M 10-Q · filed 2017-11-07 | $3.62M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $865.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.56M 10-Q · filed 2017-08-11 | $2.31M derived: sum of 3 quarters · filed 2019-03-15 | $2.94M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $693.00K 10-Q · filed 2017-05-11 | $1.44M derived: sum of 2 quarters · filed 2019-03-15 | $2.07M derived: sum of 3 quarters · filed 2019-03-15 | |
| 2016-12-31 | $749.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $1.38M derived: sum of 2 quarters · filed 2019-03-15 | $2.03M 10-K · filed 2019-03-15 | |
| 2016-09-30 | $632.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.28M 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $649.00K 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | $1.13M 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $1.22M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |